TABLE 6.
Top 10 co-cited references with the highest centrality in BRAF and MEK inhibitor resistance research in melanoma.
| Rank | Title | Journal | author(s) | Total citations |
|---|---|---|---|---|
| 1 | Improved survival with vemurafenib in melanoma with BRAF V600E Mutation | New england journal of medicine | Chapman PB | 628 |
| 2 | Improved survival with MEK Inhibition in BRAF-mutated melanoma | New england journal of medicine | Flaherty KT | 434 |
| 3 | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Nature | Nazarian R | 429 |
| 4 | Inhibition of mutated, activated BRAF in metastatic melanoma | New england journal of medicine | Flaherty KT | 414 |
| 5 | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Lancet | Hauschild A | 389 |
| 6 | Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | New england journal of medicine | Sosman JA | 376 |
| 7 | COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Nature | Johannessen CM | 315 |
| 8 | RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E) | Nature | Poulikakos PI | 310 |
| 9 | Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Cancer cell | Villanueva J | 309 |
| 10 | Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib | New england journal of medicine | Robert C | 305 |